Abstract：Objective: To evaluate the differences of flow and volume responses in patients with mild to severe chronic obstructive pulmonary disease (COPD) in bronchodilatation test. Methods: The different changes of forced expiratory volume in one second（FEV1）and forced vital capacity（FVC） in 220 patients over sixtyyearold with mild to very severe COPD (GOLD stageⅠⅣ) were analyzed retrospectively after inhaling salbutamol. Results: After inhaling β2 agonist, FEV1 and FVC of the patients with COPD at stageⅠⅣ increased remarkably, there were significant differences in the changes of FEV1 and FVC between patients with COPD compared with before treatment (P<0.01)．ΔFEV1 at stage ⅠⅡpatients with COPD increased more obviously than stage ⅢⅣ patients with COPD (P<0.01); on the contrary,ΔFVC at stage Ⅲ-Ⅳ patients with COPD improved more markedly than stage ⅠⅡ patients with COPD (P<0.01). Conclusion: There were differences between postbronchodilator flow and volume responses in patients with COPD at different stage．The reversibility of stage ⅠⅡ patients with COPD could be evaluated by FEV1, while stage ⅢⅣ patients with COPD could be evaluated by FVC.
收稿日期: 2013-09-29
作者简介: 王远征(1970—)，女，湖南醴陵人，主管技师，主要从事肺功能检查等研究。
引用本文:
王远征. 不同级别慢性阻塞性肺疾病患者对支气管舒张剂的反应[J]. 江苏大学学报:医学版, 2014, 24(02): 156-159.
WANG Yuan-zheng. Response to bronchodilator in patients with different severity chronic obstructive pulmonary disease. Journal of Jiangsu University(Medicine Edition), 2014, 24(02): 156-159.
\[1\]Rabe KF, Hurd S, Anzueto A, et al．Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary \[J\]. Am J Respir Crit Care Med, 2007, 176(6)： 532-555．\[2\]中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版)\[J\]. 中华结核和呼吸杂志， 2007， 30(1)： 8-17.\[3\]Global Initiative for Chronic Obstructive Lung Disease， Inc. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (update 2013)［M/OL］. ［2013-09-29］. http://www.goldcopd.org.\[4\]Miller MR, Hankinson J, Brusaseo V, et al. Standardization of spirometry\[J\]．Eur Respir J, 2005, 26(2): 319-338．\[5\]郑劲平.肺功能学：基础与临床\[M\]. 广州：广东科技出版社， 2007： 116-122.\[6\]田立芝，魏浩成. 支气管舒张试验的结果判断与应用进展\[J\]. 医学综述， 2011， 7(3)： 408.\[7\]顾月清，鲁顺德，顾小萍，等．雾化吸入爱喘乐对慢性阻塞性肺疾病患者肺功能的影响\[J\]． 中国实用内科杂志， 1998， 18(4)： 219-220．\[8\]Shimizu K, Hasegawa M, Makita H, et al．Comparison of airway remodelling assessed by computed tomography in asthma and COPD\[J\]. Respir Med, 201l, 105(9)： 1275-1283.\[9\]车东媛，黄侠君．慢性阻塞性肺疾病与肺构形重建\[J\]．中华结核和呼吸杂志， 1999， 22(8)： 472-474．\[10\]Nair A, Ward J, Lipworth BJ. Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry \[J\]. Ann Allergy Asthma Immunol, 2011, 107(4)： 317-322．\[11\]陈胜海，阮伟良，刘洋.不同程度的慢性阻塞性肺疾病对支气管舒张试验的反应性差异\[J\]. 国际呼吸杂志， 2012， 32(13)： 978-980.\[12\]朱蕾，任卫英. 特定性疾病情况下肺功能的动态变化\[J\]. 中华结核和呼吸杂志， 2012， 35(4)： 310-312．\[13\]Girard WM, Light RW. Should the FVC be considered in evaluating response to bronchodilator\[J\]．Chest, 1983, 84(1)： 87-89．\[14\]Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease\[J\]. Thorax, 2002, 57(10): 847-852．\[15\]Seemungal T, HarperOwen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease\[J\]．Am J Respir Crit Care Med, 2001, 164(9)： 1618-1623．\[16\]陈瑞，陈荣昌，安嘉颖，等. 深吸气量对严重慢性阻塞性肺疾病患者吸入支气管舒张剂疗效评价\[J\]. 广东医学， 2008， 29(9)： 1483-1484.\[17\]李寅环，陈荣昌，陈新，等. 吸入支气管舒张剂对慢性阻塞性肺疾病患者动态内源性呼气末正压的影响\[J\]. 中国实用内科杂志， 2007， 27(4)： 278-281.
2014, Vol. 24 
